SCHEMBL366889

SCHEMBL366889

CN(C)c1ccccc1-c1ccccc1P

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.42
ALDH1A1 P00352 4/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
NSD2 O96028 1/20 0.42
EGFR P00533 1/20 0.42
LMNA P02545 1/20 0.42
MAPK1 P28482 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
GAA P10253 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
TP53 P04637 1/20 0.39
TSHR P16473 1/20 0.39
KDM4E B2RXH2 1/20 0.38
CHEK1 O14757 1/20 0.38
NEK2 P51955 1/20 0.38
LIMK1 P53667 1/20 0.38
DYRK1A Q13627 1/20 0.38
CLK4 Q9HAZ1 1/20 0.38
KCNN4 O15554 1/20 0.36
PDK2 Q15119 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cyclohexane SCHEMBL3588452 0.94 MAPT (0.39) MAPTALDH1A1L3MBTL1NSD2EGFR
SCHEMBL15658498 0.85 MAPT (0.47) MAPTALDH1A1L3MBTL1NSD2EGFR
SCHEMBL2919461 0.85 MAPT (0.52) MAPTALDH1A1L3MBTL1NSD2EGFR
SCHEMBL18922435 0.83 MAPT (0.53) MAPTALDH1A1L3MBTL1NSD2EGFR
SCHEMBL6289829 0.80 ALDH1A1 (0.44) MAPTALDH1A1L3MBTL1NSD2EGFR
Bromide SCHEMBL28055011 0.79 MAPT (0.42) MAPTALDH1A1L3MBTL1NSD2EGFR
SCHEMBL21526429 0.77 NSD2 (0.32) MAPTALDH1A1L3MBTL1NSD2EGFR
SCHEMBL1752721 0.77 MEN1 (0.39) MAPTALDH1A1L3MBTL1LMNAMAPK1
SCHEMBL10177351 0.77 ALDH1A1 (0.47) MAPTALDH1A1L3MBTL1NSD2EGFR
SCHEMBL3965515 0.74 ALDH1A1 (0.44) MAPTALDH1A1L3MBTL1NSD2EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3461556-A1 PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS AbbVie Ireland Unlimited Company (IE) 2019-04-03 EP disclosed
EP-2593226-B1 PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS ABBVIE IRELAND UNLIMITED CO (IE) 2018-11-14 EP disclosed
CN-107949562-A The positive allosteric modulators of muscarinic M2 acceptors 拜耳制药股份公司 2018-04-20 CN disclosed
US-9809591-B2 Heterocyclic modulators of lipid synthesis 3-V BIOSCIENCES, INC. (US) 2017-11-07 US disclosed
EP-3190108-A1 HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS 3-V Biosciences, Inc. (US) 2017-07-12 EP disclosed
US-9669399-B2 Phosphine ligands for catalytic reactions ABBVIE INC. (US) 2017-06-06 US disclosed
US-9669399-B2 Phosphine ligands for catalytic reactions ABBVIE INC. (US) 2017-06-06 US disclosed
CN-106661008-A 2,5-disubstituted cyclopentane carboxylic acids for the treatment of respiratoy tract diseases 拜耳制药股份公司 2017-05-10 CN disclosed
US-20170119786-A1 HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS SAGIMET BIOSCIENCES INC. 2017-05-04 US disclosed
EP-2683244-B1 HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS 3-V BIOSCIENCES INC (US) 2017-02-01 EP disclosed
CN-1826310-A Novel aminobenzophenone compounds LEO PHARMA AS (DK) 2006-08-30 CN disclosed
WO-2006007843-A1 2-(1H-INDOLYLSULFANYL) -ARYL AMINE DERIVATIVES FOR USE IN THE TREATMENT OF AFFECTIVE DISORDERS, PAIN, ADHD AND STRESS URINARY INCONTINENCE H. LUNDBECK A/S (DK) 2006-01-26 WO disclosed
CN-1231459-C Novel aminobenzophenones LEO PHARM PROD LTD (DK) 2005-12-14 CN disclosed
CN-1561327-A Novel aminobenzophenones LEO PHARMA AS (DK) 2005-01-05 CN disclosed
CN-1181048-C Aminobenzophenones as inhibitors of IL-1 beta and TNF_alpha ������˹ҩƷ��˾ 2004-12-22 CN disclosed
CN-1174956-C Aminobenzophenones as inhibitors of IL-1 beta and TNF-alpha ������˹ҩƷ��˾ 2004-11-10 CN disclosed
CN-1487924-A Farnesyl transferase inhibitors ���Ͽع����޹�˾ 2004-04-07 CN disclosed
CN-1368950-A Novel aminobenzophenones LEO PHARM PROD LTD (DK) 2002-09-11 CN disclosed
CN-1368953-A Aminobenzophenones as inhibitors of IL-1 bata and TNF-alpha LEO PHARM PROD LTD (DK) 2002-09-11 CN disclosed
CN-1361763-A Aminobenzophenones as inhibitors of IL-1 beta and TNF_alpha LEO PHARM PROD LTD (DK) 2002-07-31 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170119786-A1 HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS FASN, FADS1, SCD MAPT 4329/4885ALDH1A1 724/4885L3MBTL1 2485/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.